The CQDM research consortium recently partnered with Germany and Belgium as part of a Canada-Europe initiative to accelerate the development of new drugs and open new markets for homegrown biotechnology companies. Building on a successful five-year partnership with France, CQDM signed agreements with Germany and Belgium that will bring together academic researchers and small- and medium-sized enterprises (SMEs) from each country. Their goal: align scientific resources and expertise to develop next-generation tools, technologies and platforms that improve, enhance or accelerate drug development—a process that can take up to 15 years and cost more than $2 billion. Projects will receive up to $1 million from CQDM, the Central Innovation Program for SMEs of the German Federal Ministry for Economic Affairs and Energy (coordinated by AiF Projekt GmbH), and the Government of Wallonia and BioWin, the Health Cluster of Wallonia (Belgium).